A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer

This study tests whether an immunotherapy drug called QL1706 (given before surgery) can help shrink colon cancer tumors in people with a specific type of colon cancer (dMMR/MSI-H) that tends to respond well to immunotherapy, with the goal of potentially making surgery easier or more curative. **You may be eligible if...** - You have been newly diagnosed with colon cancer (confirmed by biopsy) that has not been treated yet - Your cancer is stage IIB–III (locally advanced but not yet spread distantly) - Your cancer tests positive for MSI-H or dMMR (a specific molecular marker showing it is likely to respond to immunotherapy) - Your overall health is good (ECOG 0–1) - Your organ function is within acceptable levels **You may NOT be eligible if...** - You have already received any treatment for this cancer - Your cancer has spread to distant organs - You have an active autoimmune disease that required treatment in the past 2 years - You have a history of interstitial lung disease - You have an active infection requiring treatment Talk to your doctor to see if this trial is right for you.